Q3 EPS Forecast for Lisata Therapeutics Raised by Analyst

Lisata Therapeutics, Inc. (NASDAQ:LSTA – Free Report) – Research analysts at Brookline Capital Management lifted their Q3 2025 EPS estimates for shares of Lisata Therapeutics in a report released on Monday, August 11th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($0.51) per share for the quarter, up […]

Leave a Reply

Your email address will not be published.

Previous post CAB Payments (LON:CABP) Receives House Stock Rating from Shore Capital
Next post HC Wainwright Lifts Earnings Estimates for Nuvectis Pharma